Loading clinical trials...
Loading clinical trials...
A Phase 1/2a, Single- and Multiple-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO 110 in Healthy Adult Volunteers and in Adult Participants With Alpha-1 Antitrypsin Deficiency (AATD) (REWRITE)
Conditions
Interventions
KRRO-110
Locations
5
Australia
The Prince Charles Hospital
Brisbane, Queensland, Australia
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
St. Vincent's Hospital Melbourne
Melbourne, Victoria, Australia
New Zealand Clinical Research
Auckland, New Zealand
New Zealand Clinical Research
Christchurch, New Zealand
Start Date
January 13, 2025
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
December 15, 2025
Lead Sponsor
Korro Bio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions